1. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. (April 2021) Authors: Gao, Hong-Fei; Wu, Zhiyong; Lin, Ying; Song, Xiang-Yang; Cao, Yin; Chen, Qian-Jun; Zhang, Gangling; Fu, Peifen; Liu, Zhenzhen; Zhang, Liu-Lu; Yang, Ci-Qiu; Yang, Mei; Zhu, Teng; Ji, Fei; Li, Jie-Qing; Cheng, Min-Yi; Wang, Kun Journal: Therapeutic advances in medical oncology Issue: Volume 13(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol. Issue 12 (15th December 2019) Authors: Li, Lun; Yang, Benlong; Li, Hongyuan; Yin, Jian; Jin, Feng; Han, Siyuan; Liao, Ning; Shi, Jingping; Ling, Rui; Li, Zan; Ouyang, Lizhi; Wang, Xiang; Fu, Peifen; Ouyang, Zhong; Ma, Binlin; Wu, Xinhong; Wang, Haibo; Liu, Jian; Shao, Zhimin; Wu, Jiong Journal: BMJ open Issue: Volume 9:Issue 12(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study. Issue 1 (December 2016) Authors: Cao, Ayong; Zhang, Jin; Liu, Xiaoan; Wu, Weizhu; Liu, Yinhua; Fan, Zhimin; Zhang, Anqin; Zhou, Tianning; Fu, Peifen; Wang, Shu; Ouyang, Quchang; Tang, Jinhai; Jiang, Hongchuan; Zhang, Xiaohua; Pang, Da; He, Jianjun; Shi, Linxiang; Wang, Xianming; Sheng, Yuan; Mao, Dahua Journal: Health and quality of life outcomes Issue: Volume 14:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer. Issue 9 (September 2020) Authors: Zhu, Haiying; Du, Chengyong; Yuan, Meng; Fu, Peifen; He, Qiaojun; Yang, Bo; Cao, Ji Journal: Drug discovery today Issue: Volume 25:Issue 9(2020) Page Start: 1762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020. (September 2020) Authors: Li, Jianbin; Wang, Haibo; Geng, Cuizhi; Liu, Zhenzhen; Lin, Ying; Nie, Jianyun; Sun, Gang; Ouyang, Quchang; Wang, Xiaojia; Li, Xingrui; Liu, Yinhua; Chen, Qianjun; Fu, Peifen; Yao, Feng; Chen, Jishang; Chen, Yiding; Zhao, Haidong; Yin, Yongmei; Zhang, Jingjie; Chen, Jiayi Journal: EClinicalMedicine Issue: Volume 26(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The US2 protein is involved in the penetration and cell‐to‐cell spreading of DEV in vitro. (4th July 2013) Authors: Wei, Shuangshi; Liu, Xiaomei; Ma, Bo; Wu, Yihan; Liu, Yan; Gao, Mingchun; Fu, Peifen; Wang, Junwei Journal: Journal of basic microbiology Issue: Volume 54:issue 9(2014:Sep.) Page Start: 1005 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗